Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imatinib mesylate
Drug ID BADD_D01137
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status Prescription; Discontinued
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D01441
MeSH ID D000068877
PubChem ID 123596
TTD Drug ID D0AZ3C
NDC Product Code 55111-939; 64679-793; 72606-557; 63629-2067; 11722-052; 0904-6621; 60505-2901; 68382-244; 68382-245; 68001-490; 16714-705; 72485-203; 51991-376; 64679-794; 72485-202; 62068-309; 67877-634; 54893-0066; 63629-2068; 81955-0002; 72606-556; 62756-875; 68001-491; 47335-475; 70771-1394; 60505-2900; 0078-0401; 0904-6901; 60687-192; 42385-720; 0054-0249; 51991-377; 47335-472; 65344-0020; 0054-0248; 16714-704; 50268-426; 59651-240; 59651-241; 73309-059; 67877-633; 0093-7629; 42385-316; 0078-0649; 71052-670; 60687-203; 59923-723; 54893-0005; 59651-610; 0093-7630; 66499-0073; 70771-1395; 50268-427; 72969-033; 59923-724
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C30H35N7O4S
CAS Registry Number 220127-57-1
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)( =O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaLeptinP41159T79485Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.002--
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Folliculitis23.09.04.007; 11.01.12.018--
Fungal infection11.03.05.001--Not Available
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal perforation07.04.04.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.004--
Glaucoma06.03.01.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages